This report provides comprehensive information on the therapeutic development for Gliosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gliosarcoma and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Gliosarcoma Overview
- Therapeutics Development
- Pipeline Products for Gliosarcoma - Overview
- Pipeline Products for Gliosarcoma - Comparative Analysis
- Gliosarcoma - Therapeutics under Development by Companies
- Gliosarcoma - Therapeutics under Investigation by Universities/Institutes
- Gliosarcoma Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Gliosarcoma - Products under Development by Companies
- Gliosarcoma - Products under Investigation by Universities/Institutes
- Gliosarcoma - Companies Involved in Therapeutics Development
- Amgen Inc.
- Axelar AB
- Burzynski Research Institute, Inc.
- Celgene Corporation
- ERC Belgium SA
- Merck & Co., Inc.
- Millennium Pharmaceuticals, Inc.
- NewLink Genetics Corporation
- Novartis AG
- Progenics Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/trbpsl/gliosarcoma